Fibrinabbau

Fibrinabbau, also known as fibrinolysis, is a crucial physiological process in the human body. It is the natural mechanism by which blood clots, specifically those formed from fibrin, are broken down and dissolved. This process is essential for maintaining blood flow and preventing the accumulation of unnecessary clots after healing has occurred.

The primary enzyme responsible for fibrinolysis is plasmin. Plasmin circulates in the blood in an inactive precursor form called plasminogen. Activation of plasminogen to plasmin is tightly regulated by a group of enzymes called plasminogen activators. The most important of these is tissue plasminogen activator (tPA), which is released from the walls of blood vessels. Other activators, such as urokinase plasminogen activator (uPA), also play a role.

Once plasmin is activated, it degrades the fibrin meshwork that holds a blood clot together. This breakdown releases fibrin degradation products (FDPs), also known as fibrin split products. These FDPs are then cleared from the body by other cellular mechanisms. The balance between clot formation (thrombosis) and clot breakdown (fibrinolysis) is vital for hemostasis, the process of stopping bleeding.

Disruptions in fibrinolysis can have significant health consequences. Excessive fibrinolysis can lead to bleeding disorders, while insufficient fibrinolysis can contribute to thrombosis and cardiovascular diseases like heart attack and stroke. Therefore, understanding and regulating fibrinolysis is a key area of medical research and therapeutic intervention.